Hemab Therapeutics to Report Third Quarter 2026 Financial Results and Provide a Corporate Update on November 10, 2026
Key Highlights
- ➤Hemab will report third-quarter 2026 financial results November 10, 2026
- ➤Conference call begins November 10 at 8:00 a.m. ET
- ➤Hemab is developing sutacimig (HMB-001) for Glanzmann thrombasthenia and Factor VII deficiency
- ➤Hemab is developing HMB-002 for prophylactic Von Willebrand Disease treatment
- ➤Hemab is developing HMB-003 for heavy menstrual bleeding
CAMBRIDGE, Mass. and COPENHAGEN, Denmark, Nov. 03, 2026 (GLOBE NEWSWIRE) -- Hemab Therapeutics (Nasdaq: COAG), a clinical-stage biotechnology company developing therapies that reimagine the treatment of blood coagulation disorders to sustain life and human resilience, today announced that it will host a conference call on Tuesday, November 10, at 8:00 a.m. ET to discuss its financial results and provide a corporate update for the third quarter ended September 30, 2026.
Listeners can register for the webcast on the investors page of the company’s website or directly through this link. Analysts wishing to participate in the question and answer session should use this link. A replay of the webcast will be available on the company’s website approximately two hours after the call’s conclusion and will be available for approximately 90 days following the call. Those who plan on participating are advised to join 15 minutes prior to the start time.
Get started
Create a free account to read the full story.